Table 2.
Cost-effectiveness results
| Nonmetastatic prostate cancer |
Metastatic prostate cancer |
|||||
|---|---|---|---|---|---|---|
| SOC | SOC + Doc | Difference | SOC | SOC + Doc | Difference | |
| Costs (UK pounds, discounted) | ||||||
| Docetaxel | – | 1791 | 1791 | – | 1761 | 1761 |
| Monitoring | 10 912 | 10 451 | −461 | 5471 | 5641 | 170 |
| Management including toxicities | 17 400 | 18 574 | 1174 | 14 415 | 16 555 | 2139 |
| Life-extending therapies | 24 679 | 21 964 | −2715 | 27 716 | 26 611 | −1105 |
| End-of-life care | 2124 | 2084 | −40 | 4864 | 4687 | −177 |
| Total | 55 114 | 54 863 | −251 | 52 466 | 55 253 | 2787 |
| Life years (undiscounted) | 13.33 | 14.11 | 0.78 | 4.90 | 5.79 | 0.89 |
| QALYs (discounted) | ||||||
| Failure-free | 4.44 | 5.27 | 0.83 | 1.40 | 2.02 | 0.63 |
| Post-failure | 3.04 | 2.60 | −0.44 | 1.61 | 1.49 | −0.12 |
| Total | 7.48 | 7.87 | 0.39 | 3.01 | 3.51 | 0.51 |
| ICER (UK pounds/QALY) | Dominant | 5,514 | ||||
SOC = standard of care; Doc = docetaxel; ICER = incremental cost-effectiveness ratio; QALY = quality-adjusted life year.